By Charlotte Shubert

An initiative to increase transparency at the US Food and Drug Administration (FDA) moved forward on 6 January with the release of a report detailing steps the agency says it is undertaking to make its inner workings more evident to the drug industry.

The report, FDA Transparency Initiative: Improving Transparency to Regulated Industry, includes 19 so-called ‘action items’ for implementation this year, ranging from posting presentations by agency employees online to responding faster to questions from industry. The document also lists five draft proposals—now up for public comment—to further improve transparency.

(Click here to continue reading.)